SunTrust Banks, Inc. reaffirmed their buy rating on shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a report released on Friday, July 14th. The brokerage currently has a $165.00 price target on the biopharmaceutical company’s stock.
A number of other research analysts also recently commented on the stock. Cowen and Company reissued an outperform rating and set a $122.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, July 3rd. UBS AG restated a buy rating and issued a $142.00 price target (up from $140.00) on shares of Alexion Pharmaceuticals in a report on Monday, June 26th. Robert W. Baird restated a neutral rating and issued a $145.00 price target on shares of Alexion Pharmaceuticals in a report on Monday, June 26th. Leerink Swann restated an outperform rating on shares of Alexion Pharmaceuticals in a report on Thursday, June 22nd. Finally, BidaskClub upgraded shares of Alexion Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, June 20th. Five investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $156.89.
Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 132.93 on Friday. The stock’s 50 day moving average is $129.36 and its 200-day moving average is $122.92. The company has a market cap of $29.67 billion, a PE ratio of 57.65 and a beta of 1.41. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $145.42.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.48. The business had revenue of $912 million for the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company’s revenue for the quarter was up 21.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.13 EPS. Equities research analysts predict that Alexion Pharmaceuticals will post $5.60 EPS for the current fiscal year.
In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 700 shares of Alexion Pharmaceuticals stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the sale, the director now owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Bros. Advisors Lp Baker bought 1,348,955 shares of the stock in a transaction on Wednesday, June 14th. The shares were acquired at an average cost of $116.32 per share, for a total transaction of $156,910,445.60. The disclosure for this purchase can be found here. In the last three months, insiders purchased 2,019,734 shares of company stock valued at $235,606,846. 4.35% of the stock is owned by insiders.
A number of large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $3,024,000. Dimensional Fund Advisors LP boosted its stake in shares of Alexion Pharmaceuticals by 0.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 307,780 shares of the biopharmaceutical company’s stock valued at $37,660,000 after buying an additional 1,385 shares during the period. Numeric Investors LLC acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $367,000. UBS Asset Management Americas Inc. boosted its position in shares of Alexion Pharmaceuticals by 14.4% in the fourth quarter. UBS Asset Management Americas Inc. now owns 883,694 shares of the biopharmaceutical company’s stock valued at $108,119,000 after buying an additional 111,149 shares during the last quarter. Finally, Hudson Bay Capital Management LP purchased a new position in shares of Alexion Pharmaceuticals during the fourth quarter valued at $12,847,000. 95.14% of the stock is currently owned by institutional investors.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
